Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More
What does it mean for covered entities already desperate for diminishing 340B savings and revenue? As we noted in a previous post, 340B ESP is nothing less than a brazen and (in our opinion) unlawful ploy by the drug manufacturers to evade the discounts they are legally obligated to offer eligible entities — by placing … Read More
(NOTE: Over the years, we’ve served dozens of non-profit hospitals. We’ve seen the profound impact the 340B program has had in supporting their missions of serving the most vulnerable members of their communities. That said, we apologize, in advance, for the stridency of our tone on this page — but not for our sense of … Read More
Since 2019, ProxsysRx’s 340B team has generated over $500 million in 340B revenue for the health systems we serve. During that time, we’ve developed any number of strategies and tactics for overcoming 340B ESP and other manufacturer restrictions. Below are the seven key elements of our process. 1. Establishing communications between health system providers and … Read More
